Topical administration to the eye for the treatment of glaucoma is a convenient route because it increases the patient comfort. Timolol can efficiently diminish the intraocular pressure (IOP) of the eye; however the topical application as a solution of timolol maleate (TM) has poor therapeutic index and presents severe side effects. The encapsulation of timolol in nanomaterials has appeared as a technology to increase its residence time in the eye thus achieving a sustained release and consequently diminishing the doses of this drug and their number. The preparation of nanogels (NGs) based on N-isopropylacrylamide (NIPA) and acrylic acid (AAc), easily synthesized by precipitation/dispersion free radical polymerization, is reported in this p...
Ocular drug delivery is one of the most fascinating and challenging endeavours facing the research w...
We report a novel hybrid polyamidoamine (PAMAM) dendrimer hydrogel/poly(lactic-co-glycolic acid) (PL...
[[abstract]]©2002 Elsevier - In this study, controlled release ophthalmic agents for glaucoma therap...
Despite frequent scientific efforts, efficient ocular drug delivery is a major challenge for pharmac...
According to the Glaucoma Research Foundation (2013), glaucoma is the world’s second leading cause o...
Glaucoma is an ocular condition characterized by elevated intraocular pressure (IOP). Conventional t...
This work focuses on improving the effectiveness of current therapies against glaucoma by incorporat...
The self-assembling peptides Ac-(RADA)4-CONH2 and Ac-(IEIK)3I-CONH2 which form hydrogels in physiolo...
Glaucoma is a chronic eye disease and the second most leading cause of irreversible impaired vision ...
The chitosan-based thermosensitive hydrogel is one of the attractive in situ forming drug delivery s...
Topical drug delivery is one of the most challenging aspects of eye therapy. Eye drops are the most ...
Glaucoma is extensively treated with topical eye drops containing drugs. However, the retention time...
Glaucoma is a chronic disease that causes irreversible blindness. Timolol Maleate is used as first l...
According to the World Health Organization (WHO), glaucoma is the world’s second leading cause of b...
Topical instillation of eye drops remains the most common and easiest route of ocular drug administr...
Ocular drug delivery is one of the most fascinating and challenging endeavours facing the research w...
We report a novel hybrid polyamidoamine (PAMAM) dendrimer hydrogel/poly(lactic-co-glycolic acid) (PL...
[[abstract]]©2002 Elsevier - In this study, controlled release ophthalmic agents for glaucoma therap...
Despite frequent scientific efforts, efficient ocular drug delivery is a major challenge for pharmac...
According to the Glaucoma Research Foundation (2013), glaucoma is the world’s second leading cause o...
Glaucoma is an ocular condition characterized by elevated intraocular pressure (IOP). Conventional t...
This work focuses on improving the effectiveness of current therapies against glaucoma by incorporat...
The self-assembling peptides Ac-(RADA)4-CONH2 and Ac-(IEIK)3I-CONH2 which form hydrogels in physiolo...
Glaucoma is a chronic eye disease and the second most leading cause of irreversible impaired vision ...
The chitosan-based thermosensitive hydrogel is one of the attractive in situ forming drug delivery s...
Topical drug delivery is one of the most challenging aspects of eye therapy. Eye drops are the most ...
Glaucoma is extensively treated with topical eye drops containing drugs. However, the retention time...
Glaucoma is a chronic disease that causes irreversible blindness. Timolol Maleate is used as first l...
According to the World Health Organization (WHO), glaucoma is the world’s second leading cause of b...
Topical instillation of eye drops remains the most common and easiest route of ocular drug administr...
Ocular drug delivery is one of the most fascinating and challenging endeavours facing the research w...
We report a novel hybrid polyamidoamine (PAMAM) dendrimer hydrogel/poly(lactic-co-glycolic acid) (PL...
[[abstract]]©2002 Elsevier - In this study, controlled release ophthalmic agents for glaucoma therap...